Cargando…
Acute respiratory distress syndrome and severe pneumonitis after atezolizumab plus bevacizumab for hepatocellular carcinoma treatment: A case report
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and has a high mortality. However, the treatment options for advanced HCC are limited to tyrosine kinase inhibitors, such as sorafenib and lenvatinib. Since previous regimens have an insufficient efficacy, the com...
Autores principales: | Cho, Su Hyeon, You, Ga Ram, Park, Chan, Cho, Sang-Geon, Lee, Jong Eun, Choi, Sung Kyu, Cho, Sung Bum, Yoon, Jae Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237029/ https://www.ncbi.nlm.nih.gov/pubmed/37275450 http://dx.doi.org/10.4251/wjgo.v15.i5.892 |
Ejemplares similares
-
Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Kim, Tae Hyun, et al.
Publicado: (2023) -
Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
por: Satake, Tomoyuki, et al.
Publicado: (2023) -
Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study
por: Kim, Ji Hoon, et al.
Publicado: (2023) -
Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021) -
A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Watanabe, Yukinobu, et al.
Publicado: (2021)